Overview

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

Primary Objective: - To study effect of mild, moderate and severe renal impairment on the pharmacokinetics of Otamixaban. Secondary Objective: - To assess the pharmacodynamic effects of Otamixaban on subjects with mild, moderate and severe renal impairment and in matched subjects with normal renal function.

Phase:

Phase 1

Details

Lead Sponsor:

Sanofi

Treatments:

Otamixaban